Dr. Hirsch's hormone therapy rant: what's the real story?

What did @heatherhirschmd actually say?

Dr. Hirsch is responding to a 2024 Lancet paper arguing that menopause has been "over-medicalized," and she is not happy about it. Her core argument is straightforward: calling menopause over-medicalized is a made-up concept that applies a double standard women's health doesn't deserve. She draws parallels to childbirth and end-of-life care, both natural processes we actively medicalize, and argues that FDA-approved hormone therapy being "safe and efficacious" makes the Lancet's framing look less like science and more like bias. She's rallying her audience to push back directly at the paper's authors.

Her frustration is aimed specifically at a pattern she sees repeating: the same rhetorical move the Women's Health Initiative (WHI) made in 2002 when it scared millions of women off hormone therapy based on data that was later shown to be misapplied to younger, symptomatic women.

Does the science back this up?

On the core point, she is largely right, and that matters. The evidence base for hormone therapy in symptomatic menopausal women is considerably stronger than the Lancet framing suggests. The 2022 Menopause Society position statement and subsequent 2023 update confirmed that hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy women under 60 or within 10 years of menopause onset.

The WHI comparison holds up under scrutiny. Rossouw et al. (2002, JAMA) studied a population with a mean age of 63, many of whom were not symptomatic, using oral conjugated equine estrogen plus medroxyprogesterone acetate. Applying those risk signals to a 50-year-old with hot flashes and a transdermal estradiol prescription is, as multiple subsequent analyses confirmed, scientifically indefensible. Manson et al. (2013, JAMA Internal Medicine) reanalyzed WHI data by age subgroup and found that younger initiators actually showed a trend toward reduced cardiovascular risk, not increased. The "over-medicalization" framing in the Lancet does not adequately reckon with this reanalysis.

What did they get wrong (or right)?

Dr. Hirsch gets the historical argument right, and her analogy to childbirth is more than rhetorical. Maternal mortality in unassisted home births versus hospital settings is a real and documented risk gap. The medicalization-is-bad framing has genuine roots in valid critiques of pharmaceutical overreach, but applying it wholesale to symptomatic menopause management ignores that the "disease" here is debilitating symptoms affecting quality of life, bone density, cardiovascular health, and cognitive function.

Where she is less precise: she implies FDA approval itself settles the safety-and-efficacy question cleanly. It does not, fully. FDA approval establishes a regulatory threshold, not a universal clinical endorsement for every patient. There are populations, including women with certain hormone-sensitive cancers or specific clotting disorders, for whom hormone therapy carries real contraindications. Nuance matters here. She also does not distinguish between different formulations, delivery routes, or progestogen types, differences that are clinically meaningful according to Fournier et al. (2008, Breast Cancer Research and Treatment) on breast cancer risk variation by progestogen type.

What should you actually know?

The Lancet's "over-medicalization" concern is not invented out of nothing. There are legitimate critiques of direct-to-consumer menopause marketing that overstates benefits or minimizes risks for certain subgroups. But the paper's framing, as applied broadly to hormone therapy access and counseling, runs counter to the weight of current evidence and the consensus of major menopause societies globally.

The Menopause Society (formerly NAMS), the British Menopause Society, and the European Menopause and Andropause Society have all issued statements affirming that the benefits of hormone therapy outweigh the risks for most symptomatic women without contraindications when initiated before age 60 or within 10 years of menopause. Kaunitz and Manson (2015, Mayo Clinic Proceedings) outlined this risk-benefit framework in detail. If you are perimenopausal or postmenopausal and experiencing symptoms, this is a conversation to have with a clinician who knows your full history, not a decision driven by a Lancet editorial or an Instagram reel.

• Hormone therapy is not appropriate for everyone. Individual risk assessment is non-negotiable.
• The WHI data has been substantially reinterpreted since 2002, particularly for younger initiators.
• Not all hormone therapy formulations carry the same risk profile.
• "Natural" does not mean "does not require treatment."
• The over-medicalization argument has a legitimate history in healthcare, but it is being applied poorly here.

Bottom line

Dr. Hirsch's frustration is scientifically grounded in most respects. The Lancet paper echoes a pattern that genuinely did harm women's health decision-making after 2002. Her call to action is emotionally charged, and the analogy work is solid. The parts she glosses over, formulation differences, contraindicated populations, and the limits of FDA approval as a universal safety signal, are worth knowing. But the core argument? She is on the right side of the evidence.